The emblem of pharmaceutical firm Novo Nordisk is displayed in entrance of its places of work in Bagsvaerd, Copenhagen, Denmark, Feb. 4, 2026.
Tom Little | Reuters
Novo Nordisk on Tuesday mentioned it plans to slash the month-to-month checklist costs of its common weight problems and diabetes medicine within the U.S. by as much as 50% beginning in 2027, in a bid to make the therapies extra accessible to sufferers with insurance coverage protection.
The weight problems injection Wegovy, its new capsule counterpart, the diabetes shot Ozempic and the oral diabetes drug Rybelsus can have a brand new decrease checklist value of $675 per 30 days beginning on Jan. 1, 2027. The Wegovy medicines each at the moment have checklist costs of round $1,350 per 30 days, whereas the diabetes medicine have checklist costs of round $1,027 per 30 days.
For the primary time, Novo mentioned its value cuts are concentrating on insured sufferers whose out-of-pocket prices are linked to checklist costs, akin to individuals with high-deductible well being plans or coinsurance profit designs.
“Each of those affected person populations ought to, starting [in 2027], see a profit with decrease out-of-pocket burdens,” Jamey Millar, the corporate’s head of U.S. operations, advised CNBC in an interview.
He added that Novo expects enhancements in entry and uptake amongst sufferers within the industrial insurance coverage market, although the corporate is just not giving any particular expectations.
The transfer may assist Novo compete higher with Eli Lilly, which now holds the bulk share within the blockbuster GLP-1 market. Lilly’s simpler medicine and earlier foray into the direct-to-consumer house have allowed it to take the lead within the house, however the firm has but to considerably decrease the U.S. checklist costs of its medicines.
It is unclear precisely how a lot industrial insured sufferers sometimes pay out of pocket for Novo’s medicine. These sufferers could pay as little as $25 per 30 days for Novo’s medicine in “solely the very best of circumstances,” Millar mentioned.
However sufferers in high-deductible plans must pay out of pocket “kind of the total checklist value of a drug till they attain that” threshold and the insurance coverage profit kicks in, he added. Millar mentioned a few of these sufferers defer therapy totally as a result of they do not wish to shoulder that expense. The variety of sufferers utilizing high-deductible plans has elevated over time because of the trade-off of decrease premiums, he famous.
In the meantime, Millar mentioned different individuals have 25% to 33% of their coinsurance linked to the checklist costs of these medicine.
The Danish drugmaker has beforehand minimize the direct-to-consumer costs of Wegovy and Ozempic, which primarily profit cash-paying sufferers who typically haven’t got insurance coverage protection for the medicine.
Novo gives its medicine to cash-paying sufferers for $149 to $499 per 30 days, relying on the precise product and dose. Novo and Lilly have escalated a GLP-1 pricing battle over the past 12 months, particularly following the landmark “most favored nation” offers they struck with President Donald Trump in November.
The transfer additionally coincides with new, decrease Medicare costs going into impact for Novo’s weight problems and diabetes medicine in 2027 following negotiations with the federal authorities underneath the Inflation Discount Act. The brand new negotiated costs for Wegovy, Ozempic and Rybelsus will probably be $274 per 30 days.
